Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

R-CPOP as first line therapy for elderly patients with DLBCL and for patients with limited cardiac function with DLBCL

Next Previous
X
Search
Trial Profile

R-CPOP as first line therapy for elderly patients with DLBCL and for patients with limited cardiac function with DLBCL

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Aug 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pixantrone (Primary) ; Cyclophosphamide; Prednisone; Rituximab; Vincristine
  • Indications Diffuse large B cell lymphoma; Follicular lymphoma
  • Focus Therapeutic Use
  • Acronyms Pix in DLBCL first line

    • Most Recent Events

    • 17 Jun 2022 Results prospective and retrospective analysis assessing (n=28; between 2016 and 2021) efficacy and safety of first line R-CPOP in DLBCL patients with significant cardiac morbidity or high risk of anthracycline induced cardiotoxicity, presented at the 27th Congress of the European Haematology Association.
    • 24 Sep 2020 This trial has been discontinued in Germany, according to European Clinical Trials Database record.
    • 30 Aug 2020 This trial has been completed in Austria, according to European Clinical Trials Database record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top